{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:10:06Z","timestamp":1792501806871,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-025-05891-7","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:20:37Z","timestamp":1759846837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid"],"prefix":"10.1007","volume":"82","author":[{"given":"Sujie","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wufeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0416-4603","authenticated-orcid":false,"given":"Xiangmin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"9","key":"5891_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV (2024) Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 99(9):1802\u20131824. https:\/\/doi.org\/10.1002\/ajh.27422","journal-title":"Am J Hematol"},{"key":"5891_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217440","volume":"611","author":"X Dou","year":"2025","unstructured":"Dou X, Duan G, Zhong Y, Liu Y, Peng N, Wen L, Qi J, Zhou M, Zhang X, Lu J (2025) The burden of multiple myeloma in China: trends from 1990 to 2021 and forecasts for 2050. Cancer Lett 611:217440. https:\/\/doi.org\/10.1016\/j.canlet.2025.217440","journal-title":"Cancer Lett"},{"issue":"6","key":"5891_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/cancers13061353","volume":"13","author":"A D\u00edaz-Tejedor","year":"2021","unstructured":"D\u00edaz-Tejedor A, Lorenzo-Mohamed M, Puig N, Garc\u00eda-Sanz R, Mateos MV, Garayoa M, Pa\u00edno T (2021) Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression. Cancers (Basel) 13(6):1353. https:\/\/doi.org\/10.3390\/cancers13061353","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5891_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41420-024-01818-6","volume":"10","author":"L Xu","year":"2024","unstructured":"Xu L, Wen C, Xia J, Zhang H, Liang Y, Xu X (2024) Targeted immunotherapy: harnessing the immune system to battle multiple myeloma. Cell Death Discov 10(1):55. https:\/\/doi.org\/10.1038\/s41420-024-01818-6","journal-title":"Cell Death Discov"},{"issue":"6","key":"5891_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bjh.18654","volume":"200","author":"D Minakata","year":"2023","unstructured":"Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, Koyama S, Murahashi R, Nakashima H, Hyodo K, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y (2023) Relapsed and refractory multiple myeloma: a systematic review and network meta-analysis of the efficacy of novel therapies. Br J Haematol 200(6):694\u2013703. https:\/\/doi.org\/10.1111\/bjh.18654","journal-title":"Br J Haematol"},{"issue":"11","key":"5891_CR6","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.clml.2020.06.023","volume":"20","author":"V Premkumar","year":"2020","unstructured":"Premkumar V, Bhutani D, Lentzsch S (2020) Modern treatments and future directions for relapsed\/refractory multiple myeloma patients. Clin Lymphoma Myeloma Leuk 20(11):736\u2013743. https:\/\/doi.org\/10.1016\/j.clml.2020.06.023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"5891_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, Donk NWCJvd, Katodritou E, Schjesvold F, Balari AS, Rosi\u00f1ol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, Brummelen EMJv, Vanquickelberghe V, Sitthi-Amorn A, Boer CJd, Carson R, Rodriguez-Otero P, Blad\u00e9 J, Moreau P (2024) Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 390(4):301\u2013313. https:\/\/doi.org\/10.1056\/NEJMoa2312054","journal-title":"N Engl J Med"},{"key":"5891_CR8","doi-asserted-by":"publisher","unstructured":"Goldsmith SR, Foley N, Schroeder MA (2021) Daratumumab for the treatment of multiple myeloma. Drugs of today (Barcelona, Spain: 1998) 57 (10):591\u2013605. https:\/\/doi.org\/10.1358\/dot.2021.57.10.3313853","DOI":"10.1358\/dot.2021.57.10.3313853"},{"issue":"12","key":"5891_CR9","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D\u2019Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker J (2023) Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(12):1281\u20131301. https:\/\/doi.org\/10.6004\/jnccn.2023.0061","journal-title":"J Natl Compr Canc Netw"},{"issue":"Supplement 1","key":"5891_CR10","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1182\/blood-2018-99-117441","volume":"132","author":"D Viola","year":"2018","unstructured":"Viola D, Dona A, Gunes EG, Troadec E, Wu X, Branciamore S, McDonald T, Ghoda L, Streatfield A, Sanchez JF, Karanes C, Htut M, Rosenzweig M, Keats JJ, Rosen ST, Marcucci G, Krishnan A, Pichiorri F (2018) Immune mediated mechanisms of resistance to daratumumab. Blood 132(Supplement 1):3201\u20133201. https:\/\/doi.org\/10.1182\/blood-2018-99-117441","journal-title":"Blood"},{"issue":"1","key":"5891_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010167","volume":"9","author":"I Saltarella","year":"2020","unstructured":"Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, Storlazzi CT, Mariggi\u00f2 MA, Vacca A, Frassanito MA (2020) Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells 9(1):167. https:\/\/doi.org\/10.3390\/cells9010167","journal-title":"Cells"},{"issue":"23","key":"5891_CR12","doi-asserted-by":"publisher","first-page":"11986","DOI":"10.18632\/oncotarget.2388","volume":"5","author":"Y Yang","year":"2014","unstructured":"Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F (2014) NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget 5(23):11986\u201311997. https:\/\/doi.org\/10.18632\/oncotarget.2388","journal-title":"Oncotarget"},{"issue":"8","key":"5891_CR13","doi-asserted-by":"publisher","first-page":"6882","DOI":"10.1002\/jcb.26885","volume":"119","author":"N Jin","year":"2018","unstructured":"Jin N, Zhu X, Cheng F, Zhang L (2018) Disulfiram\/copper targets stem cell-like ALDH(+) population of multiple myeloma by inhibition of ALDH1A1 and hedgehog pathway. J Cell Biochem 119(8):6882\u20136893. https:\/\/doi.org\/10.1002\/jcb.26885","journal-title":"J Cell Biochem"},{"issue":"1","key":"5891_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02920-w","volume":"43","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Huang Z, Li K, Xie G, Feng Y, Wang Z, Li N, Liu R, Ding Y, Wang J, Yang J, Jia Z (2024) TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression. J Exp Clin Cancer Res 43(1):16. https:\/\/doi.org\/10.1186\/s13046-023-02920-w","journal-title":"J Exp Clin Cancer Res"},{"key":"5891_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110120","volume":"87","author":"M Poturnajova","year":"2021","unstructured":"Poturnajova M, Kozovska Z, Matuskova M (2021) Aldehyde dehydrogenase 1A1 and 1A3 isoforms - mechanism of activation and regulation in cancer. Cell Signal 87:110120. https:\/\/doi.org\/10.1016\/j.cellsig.2021.110120","journal-title":"Cell Signal"},{"key":"5891_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3904645","volume":"2019","author":"G Vassalli","year":"2019","unstructured":"Vassalli G (2019) Aldehyde dehydrogenases: not just markers, but functional regulators of stem cells. Stem Cells Int 2019:3904645. https:\/\/doi.org\/10.1155\/2019\/3904645","journal-title":"Stem Cells Int"},{"issue":"21","key":"5891_CR17","doi-asserted-by":"publisher","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","volume":"7","author":"O de Perez","year":"2023","unstructured":"de Perez O, Reiman L, Jayabalan DS, Walker ZJ, Bosma G, Keller AL, Parzych SE, Abbott D, Idler BM, Ribadeneyra D, Niesvizky R, Forsberg PA, Mark TM, Sherbenou DW (2023) CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies. Blood Adv 7(21):6430\u20136440. https:\/\/doi.org\/10.1182\/bloodadvances.2023010162","journal-title":"Blood Adv"},{"issue":"10","key":"5891_CR18","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2015.123","volume":"29","author":"IS Nijhof","year":"2015","unstructured":"Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, de Jong-Korlaar R, Yuan H, Noort WA, Klein SK, Martens AC, Doshi P, Sasser K, Mutis T, van de Donk NW (2015) Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia 29(10):2039\u20132049. https:\/\/doi.org\/10.1038\/leu.2015.123","journal-title":"Leukemia"},{"issue":"12","key":"5891_CR19","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013548. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"8","key":"5891_CR20","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"5891_CR21","doi-asserted-by":"publisher","unstructured":"Rajkumar SV (2016) Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educational Book 36e418\u2013e423. https:\/\/doi.org\/10.1200\/edbk_159009","DOI":"10.1200\/edbk_159009"},{"key":"5891_CR22","doi-asserted-by":"publisher","unstructured":"Bansal R, Kimlinger T, Gyotoku KA, Smith M, Rajkumar V, Kumar S (2021) Impact of CD138 magnetic Bead-based positive selection on bone marrow plasma cell surface markers. Clinical lymphoma, myeloma & leukemia 21. 1e48\u2013e51. https:\/\/doi.org\/10.1016\/j.clml.2020.08.003","DOI":"10.1016\/j.clml.2020.08.003"},{"issue":"7","key":"5891_CR23","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","volume":"18","author":"JL Thangaraj","year":"2021","unstructured":"Thangaraj JL, Ahn SY, Jung SH, Vo MC, Chu TH, Thi Phan MT, Kwon M, Lee KH, Kim M, Song GY, Yang DH, Ahn JS, Kim HJ, Cho D, Lee JJ (2021) Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. Cell Mol Immunol 18(7):1652\u20131661. https:\/\/doi.org\/10.1038\/s41423-021-00686-9","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"5891_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0173-0","volume":"9","author":"YX Zhu","year":"2019","unstructured":"Zhu YX, Shi C-X, Bruins LA, Wang X, Riggs DL, Porter B, Ahmann JM, de Campos CB, Braggio E, Bergsagel PL, Stewart AK (2019) Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J 9(2):19. https:\/\/doi.org\/10.1038\/s41408-019-0173-0","journal-title":"Blood Cancer J"},{"issue":"6256","key":"5891_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1126\/science.aac4690","volume":"350","author":"JI Kim","year":"2015","unstructured":"Kim JI, Ganesan S, Luo SX, Wu YW, Park E, Huang EJ, Chen L, Ding JB (2015) Aldehyde dehydrogenase 1a1 mediates a GABA synthesis pathway in midbrain dopaminergic neurons. Science 350(6256):102\u2013106. https:\/\/doi.org\/10.1126\/science.aac4690","journal-title":"Science"},{"key":"5891_CR26","doi-asserted-by":"publisher","unstructured":"Schlums H, Campbell TM, Bryceson YT (2024) Measurement of Natural Killer Cell Phenotype and Activity in Humans. In: Manual of Molecular and Clinical Laboratory Immunology. pp 292\u2013303. https:\/\/doi.org\/10.1002\/9781683674023.ch26","DOI":"10.1002\/9781683674023.ch26"},{"issue":"11","key":"5891_CR27","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/j.celrep.2018.08.027","volume":"24","author":"H Ogbomo","year":"2018","unstructured":"Ogbomo H, Timm-McCann M, Barnes T, Xiang RF, Jamil K, Ganguly A, Stack D, Huston SM, Li SS, Colarusso P, Mody CH (2018) Granule-dependent NK cell killing of Cryptococcus requires kinesin to reposition the cytolytic machinery for directed cytotoxicity. Cell Rep 24(11):3017\u20133032. https:\/\/doi.org\/10.1016\/j.celrep.2018.08.027","journal-title":"Cell Rep"},{"issue":"1","key":"5891_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/therapeutics2010002","volume":"2","author":"SK Germans","year":"2025","unstructured":"Germans SK, Kahlow CW, Chen W, Fuda F (2025) Effects of daratumumab (Anti-CD38) monoclonal antibody therapy on flow cytometry analysis in multiple myeloma. Therapeutics 2(1):2","journal-title":"Therapeutics"},{"issue":"3","key":"5891_CR29","doi-asserted-by":"publisher","first-page":"e006325","DOI":"10.1136\/jitc-2022-006325","volume":"11","author":"Z Peng","year":"2023","unstructured":"Peng Z, Wang J, Guo J, Li X, Wang S, Xie Y, Jiang H, Wang Y, Wang M, Hu M, Li Q, Wang Y, Mi J-Q, Liu Z (2023) All-trans retinoic acid improves NSD2-mediated RAR\u03b1 phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma. J Immunother Cancer 11(3):e006325. https:\/\/doi.org\/10.1136\/jitc-2022-006325","journal-title":"J Immunother Cancer"},{"issue":"7","key":"5891_CR30","doi-asserted-by":"publisher","first-page":"1599636","DOI":"10.1080\/2162402x.2019.1599636","volume":"8","author":"MC Ochoa","year":"2019","unstructured":"Ochoa MC, Perez-Ruiz E, Minute L, O\u00f1ate C, Perez G, Rodriguez I, Zabaleta A, Alignani D, Fernandez-Sendin M, Lopez A, Muntasell A, Sanmamed MF, Paiva B, Lopez-Botet M, Berraondo P, Melero I (2019) Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. Oncoimmunology 8(7):1599636. https:\/\/doi.org\/10.1080\/2162402x.2019.1599636","journal-title":"Oncoimmunology"},{"key":"5891_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123033","volume":"356","author":"K Lavudi","year":"2024","unstructured":"Lavudi K, Nuguri SM, Pandey P, Kokkanti RR, Wang Q-E (2024) ALDH and cancer stem cells: pathways, challenges, and future directions in targeted therapy. Life Sci 356:123033. https:\/\/doi.org\/10.1016\/j.lfs.2024.123033","journal-title":"Life Sci"},{"key":"5891_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.918778","volume":"12","author":"H Yue","year":"2022","unstructured":"Yue H, Hu Z, Hu R, Guo Z, Zheng Y, Wang Y, Zhou Y (2022) ALDH1A1 in cancers: bidirectional function, drug resistance, and regulatory mechanism. Front Oncol 12:918778. https:\/\/doi.org\/10.3389\/fonc.2022.918778","journal-title":"Front Oncol"},{"key":"5891_CR33","doi-asserted-by":"publisher","first-page":"6630295","DOI":"10.1155\/2021\/6630295","volume":"2021","author":"S Dwivedi","year":"2021","unstructured":"Dwivedi S, Rend\u00f3n-Huerta EP, Ortiz-Navarrete V, Monta\u00f1o LF (2021) CD38 and regulation of the immune response cells in cancer. J Oncol 2021:6630295. https:\/\/doi.org\/10.1155\/2021\/6630295","journal-title":"J Oncol"},{"issue":"1","key":"5891_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13046-018-0975-0","volume":"37","author":"V Ciccone","year":"2018","unstructured":"Ciccone V, Terzuoli E, Donnini S, Giachetti A, Morbidelli L, Ziche M (2018) Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid\/HIF-1\u03b1\/VEGF signalling in MCF-7 breast cancer cells. J Exp Clin Cancer Res 37(1):311. https:\/\/doi.org\/10.1186\/s13046-018-0975-0","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"5891_CR35","doi-asserted-by":"publisher","first-page":"10845","DOI":"10.1038\/ncomms10845","volume":"7","author":"J Bowles","year":"2016","unstructured":"Bowles J, Feng C-W, Miles K, Ineson J, Spiller C, Koopman P (2016) ALDH1A1 provides a source of meiosis-inducing retinoic acid in mouse fetal ovaries. Nat Commun 7(1):10845. https:\/\/doi.org\/10.1038\/ncomms10845","journal-title":"Nat Commun"},{"issue":"10","key":"5891_CR36","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1182\/blood.V89.10.3607","volume":"89","author":"K Mehta","year":"1997","unstructured":"Mehta K, McQueen T, Manshouri T, Andreeff M, Collins S, Albitar M (1997) Involvement of retinoic acid receptor-alpha-mediated signaling pathway in induction of CD38 cell-surface antigen. Blood 89(10):3607\u20133614","journal-title":"Blood"},{"key":"5891_CR37","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.cpccr.2024.100336","volume":"17","author":"N Biran","year":"2025","unstructured":"Biran N, Vesole DH, Parmar H, Phull P, Kumka S, Doucette K, Zenreich J, DeAgresta B, Pia AD, Biamonte L, Campanaro M, McClendon T, BaboolallAracena S, Anand P, Aleman A, Pace M, Breeze G, Ivanovski K, Layton M, Siegel DS (2025) Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature. Curr Probl Cancer: Case Rep 17:100336. https:\/\/doi.org\/10.1016\/j.cpccr.2024.100336","journal-title":"Curr Probl Cancer: Case Rep"},{"issue":"8","key":"5891_CR38","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S1470-2045(24)00341-3","volume":"25","author":"M Beksac","year":"2024","unstructured":"Beksac M (2024) Daratumumab maintenance in patients with myeloma. Lancet Oncol 25(8):947\u2013948. https:\/\/doi.org\/10.1016\/S1470-2045(24)00341-3","journal-title":"Lancet Oncol"},{"key":"5891_CR39","doi-asserted-by":"publisher","first-page":"153303382211065","DOI":"10.1177\/15330338221106563","volume":"21","author":"F Shen","year":"2022","unstructured":"Shen F, Shen W (2022) Isatuximab in the treatment of multiple myeloma: a review and comparison with daratumumab. Technol Cancer Res Treat 21:15330338221106564. https:\/\/doi.org\/10.1177\/15330338221106563","journal-title":"Technol Cancer Res Treat"},{"key":"5891_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06343-9","author":"M Dimopoulos","year":"2025","unstructured":"Dimopoulos M, Sunami K, Leleu X, Vij R, Gasparetto C, Suzuki K, Mac\u00e9 S, Tada K, Hirakawa M, Iida S (2025) Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trials. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-025-06343-9","journal-title":"Ann Hematol"},{"issue":"4","key":"5891_CR41","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3390\/jcm9041195","volume":"9","author":"LE Franssen","year":"2020","unstructured":"Franssen LE, Stege CAM, Zweegman S, van de Donk N, Nijhof IS (2020) Resistance mechanisms towards CD38-Directed antibody therapy in multiple myeloma. J Clin Med 9(4):1195. https:\/\/doi.org\/10.3390\/jcm9041195","journal-title":"J Clin Med"},{"issue":"72","key":"5891_CR42","doi-asserted-by":"publisher","first-page":"33621","DOI":"10.18632\/oncotarget.26098","volume":"9","author":"J Krejcik","year":"2018","unstructured":"Krejcik J, van de Donk N (2018) Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma. Oncotarget 9(72):33621\u201333622. https:\/\/doi.org\/10.18632\/oncotarget.26098","journal-title":"Oncotarget"},{"issue":"20","key":"5891_CR43","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood.2019004332","volume":"136","author":"D Ogiya","year":"2020","unstructured":"Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai Y-T, Adamia S, Ando K, Hideshima T, Anderson KC (2020) The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood 136(20):2334\u20132345. https:\/\/doi.org\/10.1182\/blood.2019004332","journal-title":"Blood"},{"issue":"1","key":"5891_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-025-07897-0","volume":"8","author":"H Guo","year":"2025","unstructured":"Guo H, Lin Z, Zhang D, Qin Q, Li Z, Yin Y, Chen J, Guo W (2025) ZDHHC9-mediated CD38 palmitoylation stabilizes CD38 expression and promotes pancreatic cancer growth. Commun Biol 8(1):477. https:\/\/doi.org\/10.1038\/s42003-025-07897-0","journal-title":"Commun Biol"},{"issue":"Supplement 1","key":"5891_CR45","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood-2024-201056","volume":"144","author":"B Diamond","year":"2024","unstructured":"Diamond B, Baughn LB, Poorebrahim M, Poos AM, Lee H, Kaddoura M, Wiedmeier-Nutor JE, Durante M, Otteson G, Jevremovic D, Tang H, Frohling S, Papadimitriou M, Ziccheddu B, Jelinek T, Landgren O, Neri P, Bergsagel PL, Braggio E, Kumar S, Raab MS, Fonseca R, Bahlis NJ, Weinhold N, Maura F (2024) Convergent evolution towards CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma. Blood 144(Supplement 1):592\u2013592. https:\/\/doi.org\/10.1182\/blood-2024-201056","journal-title":"Blood"},{"issue":"1","key":"5891_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41698-023-00411-x","volume":"7","author":"K Lavudi","year":"2023","unstructured":"Lavudi K, Banerjee A, Li N, Yang Y, Cai S, Bai X, Zhang X, Li A, Wani E, Yang S-M, Zhang J, Rai G, Backes F, Patnaik S, Guo P, Wang Q-E (2023) ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase \u03b8 expression. Npj Precision Oncol 7(1):66. https:\/\/doi.org\/10.1038\/s41698-023-00411-x","journal-title":"Npj Precision Oncol"},{"key":"5891_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.918778","author":"H Yue","year":"2022","unstructured":"Yue H, Hu Z, Hu R, Guo Z, Zheng Y, Wang Y, Zhou Y (2022) ALDH1A1 in cancers: bidirectional function, drug resistance, and regulatory mechanism. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.918778","journal-title":"Front Oncol"},{"key":"5891_CR48","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.2147\/ott.S107957","volume":"9","author":"J Jiang","year":"2016","unstructured":"Jiang J, Liu Y, Tang Y, Li L, Zeng R, Zeng S, Zhong M (2016) ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2\/STAT3 pathway. Onco Targets Ther 9:5349\u20135360. https:\/\/doi.org\/10.2147\/ott.S107957","journal-title":"Onco Targets Ther"},{"issue":"8","key":"5891_CR49","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41419-024-06943-9","volume":"15","author":"M Wang","year":"2024","unstructured":"Wang M, Wang T, Wang J, Yang Y, Li X, Chen H, Liao J (2024) ALDH1A1 promotes immune escape of tumor cells through ZBTB7B-glycolysis pathway. Cell Death Dis 15(8):568. https:\/\/doi.org\/10.1038\/s41419-024-06943-9","journal-title":"Cell Death Dis"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05891-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-025-05891-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05891-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:20:37Z","timestamp":1759846837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-025-05891-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5891"],"URL":"https:\/\/doi.org\/10.1007\/s00018-025-05891-7","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board at the Zhejiang Provincial People\u2019s Hospital, with approval number of QT2025029.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"\u00a0Competing interest"}}],"article-number":"352"}}